Karolinska Development AB (publ)

Stockholm Stock Exchange KDEV.ST

Karolinska Development AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 123.06 M

Karolinska Development AB (publ) Shareholders' Equity is USD 123.06 M for the year ending December 31, 2023. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Karolinska Development AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 106.92 M, a 10.23% change year over year.
Karolinska Development AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 96.99 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: KDEV.ST

Karolinska Development AB (publ)

CEO	Dr. Viktor Drvota M.D., Ph.D.
IPO Date	April 15, 2011
Location	Sweden
Headquarters	Tomtebodavägen 23 A
Employees	8
Sector	Finance
Industries Venture Capital Hedge Funds Investment Banking & Asset Management Private Equity

Description

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years